Investors in early stage in vitro diagnostic technologies
ABOUT
Who We Are
​
CS Ventures is the corporate venture fund initiative of Canterbury Scientific Ltd., a leading OEM developer and supplier of high quality in vitro diagnostic controls and calibrators for diabetic and haemoglobinopathy applications worldwide. CS Ventures was established in 2019 to invest in promising IVD opportunities that align with Canterbury Scientific’s existing capabilities and to diversify into applications beyond diabetes mellitus.
​
Our non-confidential investments include Aptatek (USA) and MiMARK (Spain).
​
What We Are Looking For
​
CS Ventures makes strategically aligned investments. The type of technology we are interested in is limited to novel IVD technologies, but we are interested in a broad range of applications. We are somewhat flexible regarding deal structure, deal size and stage of development. If you have any questions regarding our interests or want to share your technology, please use the form at the bottom of this page.
Type of Technology: Novel in vitro diagnostic technologies that use non-nucleotide biological reagents and/or controls that are not currently readily available or tests that utilize a lateral flow device.
​
Intellectual Property: technology must have protectable IP or the potential for IP. We are interested in novel biomarkers rather than novel platform technologies
​
Application Area: any disease area where there is an unmet need except diabetes mellitus
​
Stage of Development: early-stage technologies – from human proof of concept and prototype assay stage
​
Deal Structure: a broad range of investment and partnering structures but with a preference for in-licensing
​
Geographical Scope: jurisdiction agnostic, we are interested in technologies from all around the world
What We Offer
​
The size and structure of capital investments CS Ventures makes depends on the specific opportunity. In addition to capital, CS Ventures is supported by Canterbury Scientific’s extensive experience and expertise in upscaling the manufacturing of biologics, quality control management, regulatory processes and approvals, which include FDA and CE Mark. Canterbury Scientific is also well established in the global network of MedTech companies and works closely with many of the major players in the industry. CS Ventures seeks to add value to portfolio technologies using the know how and expertise that Canterbury Scientific has acquired over more than 30 years in the industry.
​
OUR TEAM
Dr Robert Feldman
CS Ventures Head
Robert combines over 30 years of medical, academic, and business expertise in the biotechnology and medical technology industries. A qualified medical practitioner, he studied at three of the world’s top ten universities, earning his medical degree in London and a PhD in the Netherlands. His career includes roles at Harvard Medical School and Imperial College London, as well as founding multiple biotechnology companies in the UK.
Robert has led European operations for Paramount Biosciences, LLC, and served as Entrepreneur in Residence at Imperial Innovations, London. In 2010, he moved to New Zealand to become Executive Director at Pacific Channel, a leading venture investment firm.
He possesses a breadth of medical and research expertise encompassing therapeutics, devices, diagnostics, and functional health preparations, with a proven ability to commercialize early-stage technologies. Robert’s global experience includes successful business development and licensing deals across Europe, the USA, Australia, Russia, South Korea, and New Zealand. With a nuanced understanding of the challenges in bringing innovations to market, he excels at transforming early-stage technologies into impactful solutions that advance human health.
Helen Haywood
Technology Analyst
Helen, a Biomedical Science graduate with hands-on experience in start-ups and a proactive approach to industry engagement, brings a robust foundation in laboratory work and practical insights to this role.
Her passion for bridging the gap between academic research and industry applications aligns with our mission to help the development of impactful technologies that enhance healthcare delivery.
With a background in science communication, innovation, and engagement, Helen is equipped with the essential skills to advance meaningful scientific solutions, ensuring that our approach is both scientifically sound and socially relevant.
CONTACT
CS Ventures
If you would like to get in touch or have an in vitro diagnostic opportunity that you’d like to discuss, please fill out the following form. We look forward to hearing from you!
